Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

C4 Therapeutics, Inc.

NASDAQ: CCCC · Life Sciences · 4 alerts · CIK 1662579

Share price
$2.65Close, Nov 16
Market cap
$348M
Shares outstanding
131.32MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All C4 Therapeutics, Inc. filings on SEC EDGAR ↗

4:10 PM ET Form 4
Insider Selling

C4 Therapeutics CFO Kendra Adams Sells $122K of Stock

Kendra Adams, CFO, sold 45,173 shares of C4 Therapeutics, Inc. at $2.71 a share, worth $122K in total on Nov 12, 2026. Shares held after the trade: 337,150 (-11.8%).

Value
$122K
Shares
45,173
Price
$2.71
Role
CFO
Holding change
-11.8%
Trade date
Nov 12, 2026
7:16 AM ET 8-K
Financial Results

C4 Therapeutics Financial Results

C4 Therapeutics reported financial results for the third quarter of 2026, highlighting clinical progress for its lead candidate cemsidomide. The company remains on track to complete enrollment for the Phase 2 MOMENTUM trial in Q1 2027 and expects initial data from multiple combination cohorts in mid-to-late 2027.

“Throughout the year, we have continued to build evidence supporting cemsidomide’s potential as a backbone therapy across the multiple myeloma treatment landscape while advancing our clinical development plan to evaluate cemsidomide in late and earlier lines of therapy.”

Andrew Hirsch, president and chief executive officer of C4 Therapeutics

“With data expected from these trials in 2027, we believe next year will be pivotal in establishing cemsidomide’s therapeutic profile and its potential to address the significant unmet need of patients with multiple myeloma across an evolving standard of care.”

Andrew Hirsch, president and chief executive officer of C4 Therapeutics
7:05 AM ET 8-K
Clinical Trial Data

C4 Therapeutics Clinical Trial Data

C4 Therapeutics presented new biomarker data from its Phase 1 trial of cemsidomide with dexamethasone and preliminary Phase 1b data for cemsidomide combined with elranatamab at the 23rd International Myeloma Society Annual Meeting. The data demonstrated that cemsidomide drives T-cell activation and prevents T-cell exhaustion, supporting its potential as a combination partner for immune-based therapies in relapsed/refractory multiple myeloma. Additionally, the 75 µg dose level in the Phase 1b trial was declared safe, allowing the study to advance to dose expansion and escalation cohorts.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.